Skip to Main Content

After a dismal first quarter for biotechs with Wall Street aspirations, a pair of small drug developers pulled off successful IPOs, suggesting 2017 may provide a warmer climate for an industry on the mend.

Two companies — BioHaven Pharmaceuticals and UroGen Pharma — successfully went public on Thursday, marking the fourth and fifth biotech IPOs of the second quarter. That tops the first quarter’s entire tally, according to Renaissance Capital, suggesting biotech is on the rebound after a four-year IPO nadir.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!